[1] Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R (2017) The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Autoimmun Rev 16(12): 1185-1195
[2] McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23): 2205-19
[3] Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055): 2023-2038.
[4] David JM, Mattei RA, Mauad JL, De Almeida LG, Nogueira MA, Menolli PV, et al (2013) Clinical and laboratory features of patients with rheumatoid arthritis diagnosed at rheumatology services in the Brazilian municipality of Cascavel, PR, Brazil. Rev Bras Reumatol 53(1): 57-65
[5] Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1): 3-15
[6] Pattloch D, Richter A, Manger B, Dockhorn R, Meier L, Tony HP, et al (2017) The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision. Z Rheumatol 76(3): 210-218
[7] Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-d'Elia H, Askling J, et al (2018) Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Annrheumdis 77(5): 650-657
[8] Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Favalli GE, et al (2016) Tailored First-Line Biologic Therapy in Patients with Rheumatoid Arthritis, Spondyloarthritis and Psoriatic Arthritis. Semarthrit 45(5): 519-32
[9] Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73(1): 86-94.
[10] Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan AC, et al (2012) A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 12;2(6). pii: e001395
[11] Gabay C, Emery P, Vollenhoven VR, Dikranian A, Alten R, Pavelka K, et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381(9877): 1541-50
[12] Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3): 492-509
[13] Monti S, Klersy C, Gorla R, Sarzi-Puttini P, Atzeni F, Pellerito R, et al (2017) Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol 36(4): 753-761
[14] Hmamouchi I, Abouqal R, Achemlal L, Fadoua Allali, Rachid Bahiri, Imane El Bouchti, et al (2019) The Moroccan registry of biological therapies in rheumatic diseases (RBSMR): methods and preliminaries results. Rev Mar Rhum 49:32-7
[15] De Lucena Valim JM, Gonçalves Chaer FG, Guimarães da Silveira FD, Da Silva E Lima VP, Batista de Souza BD (2018) Switching of biological therapies in Brazilian patients with rheumatoid arthritis. Future Sci OA 5(1): FSO355.
[16] Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69(1): 88-96
[17] Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP (2015) Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm 21(5): 409-23
[18] Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomšič M, et al (2016) Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis 75(7): 1336-42
[19] Martin WJ, Shim M, Paulus HE, Chaudhari S, Feng J, Elashoff D, et al (2014) Older age at rheumatoid arthritis onset and comorbidities correlate with less health assessment questionnaire-disability index and clinical disease activity index response to etanercept in the RADIUS 2 registry. J Clin Rheumatol 20(6): 301-5
[20] Sugihara T, Harigai M (2016) Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs. Drugs Aging 33(2): 97-107
[21] Radovits BJ, Fransen J, Eijsbouts A, van Riel PLCM, Laan RFJM (2009) Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford) 48(8): 906-10
[22] Morsley K, Kilner T, Steuer A (2015) Biologics prescribing for rheumatoid arthritis in older patients: a single-center retrospective cross-sectional study. Rheumatol Ther. Rheumatol Ther 2(2): 165-172